Junichi Kurebayashi

Summary

Affiliation: Kawasaki Medical School
Country: Japan

Publications

  1. ncbi request reprint Combined measurement of serum sialyl Lewis X with serum CA15-3 in breast cancer patients
    Junichi Kurebayashi
    Department of Breast and Thyroid Surgery, Kawasaki Medical School, Kurashiki, Okayama 701 0192, Japan
    Jpn J Clin Oncol 36:150-3. 2006
  2. ncbi request reprint Current clinical trials of endocrine therapy for breast cancer
    Junichi Kurebayashi
    Department of Breast and Thyroid Surgery, Kawasaki Medical School, Japan
    Breast Cancer 14:200-14. 2007
  3. ncbi request reprint [A case of paclitaxel and trastuzumab-resistant recurrent breast cancer with liver metastasis responding to S-1]
    Tsunehisa Nomura
    Dept of Breast and Thyroid Surgery, Kawasaki Medical School
    Gan To Kagaku Ryoho 35:1607-10. 2008
  4. doi request reprint Marked lymphovascular invasion, progesterone receptor negativity, and high Ki67 labeling index predict poor outcome in breast cancer patients treated with endocrine therapy alone
    Junichi Kurebayashi
    Department of Breast and Thyroid Surgery, Kawasaki Medical School, Kurashiki, Okayama, 701 0192, Japan
    Breast Cancer 21:214-22. 2014
  5. ncbi request reprint A pure antiestrogen, ICI 182,780, stimulates the growth of tamoxifen-resistant KPL-1 human breast cancer cells in vivo but not in vitro
    J Kurebayashi
    Department of Breast and Thyroid Surgery, Okayama, Japan
    Oncology 55:23-34. 1998
  6. doi request reprint Adjuvant therapy for premenopausal patients with early breast cancer
    Junichi Kurebayashi
    Department of Breast and Thyroid Surgery, Kawasaki Medical School, Kurashiki, Okayama, Japan
    Curr Opin Obstet Gynecol 20:51-4. 2008
  7. ncbi request reprint The prevalence of intrinsic subtypes and prognosis in breast cancer patients of different races
    Junichi Kurebayashi
    Department of Breast and Thyroid Surgery, Kawasaki Medical School, 577 Matsushima, Kurashiki, Okayama 701 0192, Japan
    Breast 16:S72-7. 2007
  8. ncbi request reprint Additive antitumor effect of concurrent treatment of 4-hydroxy tamoxifen with 5-fluorouracil but not with doxorubicin in estrogen receptor-positive breast cancer cells
    Junichi Kurebayashi
    Department of Breast and Thyroid Surgery, Kawasaki Medical School, 577 Matsushima, Kurashiki, Okayama, 701 0192, Japan
    Cancer Chemother Pharmacol 59:515-25. 2007
  9. ncbi request reprint Establishment of enzyme-linked immunosorbent assays for thymidylate synthase and dihydropyriminide dehydrogenase in cancer tissues
    Junichi Kurebayashi
    Department of Breast and Thyroid Surgery, Kawasaki Medical School, Kurashiki, Okayama 701 0192, Japan
    Oncol Rep 11:973-9. 2004
  10. ncbi request reprint Loss of BRCA1 expression may predict shorter time-to-progression in metastatic breast cancer patients treated with taxanes
    Junichi Kurebayashi
    Department of Breast and Thyroid Surgery, Kawasaki Medical School, Okayama, Japan
    Anticancer Res 26:695-701. 2006

Detail Information

Publications63

  1. ncbi request reprint Combined measurement of serum sialyl Lewis X with serum CA15-3 in breast cancer patients
    Junichi Kurebayashi
    Department of Breast and Thyroid Surgery, Kawasaki Medical School, Kurashiki, Okayama 701 0192, Japan
    Jpn J Clin Oncol 36:150-3. 2006
    ..To increase its sensitivity, the combined measurement of other tumor markers with CA15-3 was investigated...
  2. ncbi request reprint Current clinical trials of endocrine therapy for breast cancer
    Junichi Kurebayashi
    Department of Breast and Thyroid Surgery, Kawasaki Medical School, Japan
    Breast Cancer 14:200-14. 2007
    ..The current status and recent advances in endocrine therapy for breast cancer are reviewed based on the results of current clinical trials. Future perspectives of endocrine therapy are also discussed...
  3. ncbi request reprint [A case of paclitaxel and trastuzumab-resistant recurrent breast cancer with liver metastasis responding to S-1]
    Tsunehisa Nomura
    Dept of Breast and Thyroid Surgery, Kawasaki Medical School
    Gan To Kagaku Ryoho 35:1607-10. 2008
    ..Only rash (grade 1) was observed during treatment. The treatment of S-1 is thought to be effective for taxane-resistant recurrent breast cancer...
  4. doi request reprint Marked lymphovascular invasion, progesterone receptor negativity, and high Ki67 labeling index predict poor outcome in breast cancer patients treated with endocrine therapy alone
    Junichi Kurebayashi
    Department of Breast and Thyroid Surgery, Kawasaki Medical School, Kurashiki, Okayama, 701 0192, Japan
    Breast Cancer 21:214-22. 2014
    ..To identify patients who should be treated with additional chemotherapy, prognostic factors were investigated in breast cancer patients postoperatively treated with endocrine therapy alone...
  5. ncbi request reprint A pure antiestrogen, ICI 182,780, stimulates the growth of tamoxifen-resistant KPL-1 human breast cancer cells in vivo but not in vitro
    J Kurebayashi
    Department of Breast and Thyroid Surgery, Okayama, Japan
    Oncology 55:23-34. 1998
    ..Paracrine interaction between tumor cells and stromal cells mediated by growth factors, such as FGF-1, might be a key factor to explain the unique hormone responsiveness of KPL-1 cells...
  6. doi request reprint Adjuvant therapy for premenopausal patients with early breast cancer
    Junichi Kurebayashi
    Department of Breast and Thyroid Surgery, Kawasaki Medical School, Kurashiki, Okayama, Japan
    Curr Opin Obstet Gynecol 20:51-4. 2008
    ..Current topics on adjuvant therapy for premenopausal patients with breast cancer are reviewed...
  7. ncbi request reprint The prevalence of intrinsic subtypes and prognosis in breast cancer patients of different races
    Junichi Kurebayashi
    Department of Breast and Thyroid Surgery, Kawasaki Medical School, 577 Matsushima, Kurashiki, Okayama 701 0192, Japan
    Breast 16:S72-7. 2007
    ..The prevalence of intrinsic subtypes should be taken into account when analyzing survival data in a multi-racial/international clinical study...
  8. ncbi request reprint Additive antitumor effect of concurrent treatment of 4-hydroxy tamoxifen with 5-fluorouracil but not with doxorubicin in estrogen receptor-positive breast cancer cells
    Junichi Kurebayashi
    Department of Breast and Thyroid Surgery, Kawasaki Medical School, 577 Matsushima, Kurashiki, Okayama, 701 0192, Japan
    Cancer Chemother Pharmacol 59:515-25. 2007
    ..This study was conducted to clarify the hypothesis that there are differential interactions among TAM and chemotherapeutic agents...
  9. ncbi request reprint Establishment of enzyme-linked immunosorbent assays for thymidylate synthase and dihydropyriminide dehydrogenase in cancer tissues
    Junichi Kurebayashi
    Department of Breast and Thyroid Surgery, Kawasaki Medical School, Kurashiki, Okayama 701 0192, Japan
    Oncol Rep 11:973-9. 2004
    ..Further studies are warranted to investigate predictive and prognostic values of intratumoral TS and DPD levels in various malignancies using these ELISAs...
  10. ncbi request reprint Loss of BRCA1 expression may predict shorter time-to-progression in metastatic breast cancer patients treated with taxanes
    Junichi Kurebayashi
    Department of Breast and Thyroid Surgery, Kawasaki Medical School, Okayama, Japan
    Anticancer Res 26:695-701. 2006
    ..Preclinical studies have indicated that BRCA1 functions differentially to modulate the chemosensitivity of cancer cells...
  11. ncbi request reprint Additive antitumor effects of gefitinib and imatinib on anaplastic thyroid cancer cells
    Junichi Kurebayashi
    Department of Breast and Thyroid Surgery, Kawasaki Medical School, Kurashiki, 701 0192, Okayama, Japan
    Cancer Chemother Pharmacol 58:460-70. 2006
    ..These findings prompted us to investigate the antitumor activity of molecular targeting agents in thyroid cancer cells...
  12. ncbi request reprint Resistance to endocrine therapy in breast cancer
    Junichi Kurebayashi
    Department of Breast and Thyroid Surgery, Kawasaki Medical School, 577 Matsushima, Kurashiki, Okayama, 701 0192, Japan
    Cancer Chemother Pharmacol 56:39-46. 2005
    ..Molecular mechanisms responsible for endocrine resistance in breast cancer are reviewed and possible therapeutic strategies against this resistance are discussed...
  13. doi request reprint Possible treatment strategies for triple-negative breast cancer on the basis of molecular characteristics
    Junichi Kurebayashi
    Department of Breast and Thyroid Surgery, Kawasaki Medical School, 577 Matsushima, Kurashiki, Okayama 701 0192, Japan
    Breast Cancer 16:275-80. 2009
    ..Further biological characterization of TN breast cancer is needed to develop more specific treatment strategies against TN breast cancer...
  14. doi request reprint Preclinical rationale for combined use of endocrine therapy and 5-fluorouracil but neither doxorubicin nor paclitaxel in the treatment of endocrine-responsive breast cancer
    Junichi Kurebayashi
    Department of Breast and Thyroid Surgery, Kawasaki Medical School, Matsushima, Kurashiki, Okayama Japan
    Cancer Chemother Pharmacol 65:219-25. 2010
    ..We further clarified the effects of combined administration of endocrine therapy with chemotherapeutic agents in this study...
  15. pmc Preferential antitumor effect of the Src inhibitor dasatinib associated with a decreased proportion of aldehyde dehydrogenase 1-positive cells in breast cancer cells of the basal B subtype
    Junichi Kurebayashi
    Department of Breast and Thyroid Surgery, Kawasaki Medical School, 577 Matsushima, Kurashiki, Okayama 701 0192, Japan
    BMC Cancer 10:568. 2010
    ..To clarify this finding and further investigate combined antitumor effects of dasatinib with cytotoxic agents, a panel of breast cancer cell lines of various subtypes was treated with dasatinib and/or chemotherapeutic agents...
  16. ncbi request reprint Expression of vascular endothelial growth factor (VEGF) family members in breast cancer
    J Kurebayashi
    Department of Breast and Thyroid Surgery, Kawasaki Medical School, Okayama
    Jpn J Cancer Res 90:977-81. 1999
    ..These findings suggest a possible relationship between the expression level of VEGF-C and/or VEGF-D and the development of lymphatic tumor spread...
  17. ncbi request reprint Expression levels of estrogen receptor-alpha, estrogen receptor-beta, coactivators, and corepressors in breast cancer
    J Kurebayashi
    Department of Breast and Thyroid Surgery, Kawasaki Medical School, Okayama, Japan
    Clin Cancer Res 6:512-8. 2000
    ....
  18. ncbi request reprint All-trans-retinoic acid modulates expression levels of thyroglobulin and cytokines in a new human poorly differentiated papillary thyroid carcinoma cell line, KTC-1
    J Kurebayashi
    Department of Breast and Thyroid Surgery, Kawasaki Medical School, Kurashiki, Okayama, Japan
    J Clin Endocrinol Metab 85:2889-96. 2000
    ..This cell line may be useful for studying redifferentiation therapy for thyroid carcinoma...
  19. ncbi request reprint Endocrine therapies for patients with recurrent breast cancer: predictive factors for responses to first- and second-line endocrine therapies
    J Kurebayashi
    Department of Breast and Thyroid Surgery, Kawasaki Medical School, Kurashiki, Okayama, Japan
    Oncology 59:31-7. 2000
    ....
  20. ncbi request reprint Hypoxia reduces hormone responsiveness of human breast cancer cells
    J Kurebayashi
    Department of Breast and Thyroid Surgery, Kawasaki Medical School, Kurashiki, Okayama 701 0192
    Jpn J Cancer Res 92:1093-101. 2001
    ..These findings indicate that hypoxia down-regulates ER-alpha expression as well as ER-alpha function in breast cancer cells. These processes may lead to an acquired resistance to hormonal therapy in breast cancer...
  21. ncbi request reprint A radicicol derivative, KF58333, inhibits expression of hypoxia-inducible factor-1alpha and vascular endothelial growth factor, angiogenesis and growth of human breast cancer xenografts
    J Kurebayashi
    Department of Breast and Thyroid Surgery, Kawasaki Medical School, Kurashiki, Okayama 701 0192, Japan
    Jpn J Cancer Res 92:1342-51. 2001
    ..It is suggested that the post-transcriptional down-regulation of HIF-1alpha expression by this agent may result in a decrease of VEGF expression and tumor angiogenesis...
  22. ncbi request reprint Medroxyprogesterone acetate decreases secretion of interleukin-6 and parathyroid hormone-related protein in a new anaplastic thyroid cancer cell line, KTC-2
    Junichi Kurebayashi
    Department of Breast and Thyroid Surgery, Kawasaki Medical School, Kurashiki, Japan
    Thyroid 13:249-58. 2003
    ..This KTC-2 cell line may be a suitable model for developing new strategies against paraneoplastic syndromes caused by anaplastic thyroid cancer...
  23. doi request reprint The cell cycle profile test is a prognostic indicator for breast cancer patients treated with postoperative 5-fluorouracil-based chemotherapy
    Junichi Kurebayashi
    Department of Breast and Thyroid Surgery, Kawasaki Medical School, 577 Matsushima, Kurashiki, Okayama 701 0192, Japan
    Jpn J Clin Oncol 41:739-46. 2011
    ..To further clarify the prognostic value, we applied this to breast cancer patients treated with postoperative 5-fluorouracil-based chemotherapy...
  24. ncbi request reprint Expression of HER family receptors and effects of anti-HER2-antibody on human myeloma cell lines
    Takemi Otsuki
    Department of Hygiene, Kawasaki Medical School, Okayama 701 0192, Japan
    Int J Oncol 23:1135-41. 2003
    ..Moreover, combination treatment with antiestrogen had an additive growth inhibitory effect. Such analyses may provide for use of rhumAbHER2 in myeloma treatment for the future...
  25. ncbi request reprint Significance of serum tumor markers in monitoring advanced breast cancer patients treated with systemic therapy: a prospective study
    Junichi Kurebayashi
    Department of Breast and Thyroid Surgery, Kawasaki Medical School, 577 Matsushima, Kurashiki, Okayama 701 0192, Japan
    Breast Cancer 11:389-95. 2004
    ..The significance of serum tumor markers in monitoring advanced breast cancer patients is still controversial. To clarify this issue, the Tumor Marker Study Group of the Japanese Breast Cancer Society conducted a prospective study...
  26. ncbi request reprint Effect of hypoxia on human seminoma cells
    Tomohiro Fujii
    Department of Urology, Kawasaki Medical School, Okayama 701 0192, Japan
    Int J Oncol 20:955-62. 2002
    ..The adhesion molecules were only slightly altered...
  27. ncbi request reprint Expression of vascular endothelial growth factor family messenger RNA in diseased thyroid tissues
    Katsuhiro Tanaka
    Department of Breast and Thyroid Surgery, Kawasaki Medical School, Kurashiki, Japan
    Surg Today 32:761-8. 2002
    ..We investigated the expression of each VEGF gene in diseased thyroids using the multiplex reverse transcription-polymerase chain reaction (RT-PCR) method...
  28. doi request reprint Preoperative dynamic lymphoscintigraphy predicts sentinel lymph node metastasis in patients with early breast cancer
    Kazutaka Nakashima
    Department of Breast and Thyroid Surgery, Kawasaki Medical School, Matsushima, Kurashiki, Okayama, Japan
    Breast Cancer 17:17-21. 2010
    ..Preoperative lymphoscintigraphy is commonly used in sentinel lymph node biopsy (SLNB) for patients with early breast cancer; however, its significance to predict SLN metastasis remains to be determined...
  29. ncbi request reprint Retrospective analysis of predictive factors for recurrence after curatively resected papillary thyroid carcinoma
    Katsuhiro Tanaka
    Department of Breast and Thyroid Surgery, Kawasaki Medical School, 577 Matsushima, Kurashiki, 701 0192, Japan
    Surg Today 35:714-9. 2005
    ..This retrospective study analyzes the predictive factors after curative surgery for papillary thyroid carcinoma (PTC)...
  30. ncbi request reprint Inhibition of infiltration and angiogenesis by thrombospondin-1 in papillary thyroid carcinoma
    Katsuhiro Tanaka
    The Department of Breast and Thyroid Surgery, Kawasaki Medical School, Kurashiki 701 0192, Japan
    Clin Cancer Res 8:1125-31. 2002
    ..Angiogenesis is essential for tumor growth and is controlled by the balance between angiogenic and antiangiogenic factors. We studied the expression of angiogenic factors and antiangiogenic factors in papillary thyroid carcinoma...
  31. ncbi request reprint Significance of serum carcinoembryonic antigen and CA 15-3 in monitoring advanced breast cancer patients treated with systemic therapy: a large-scale retrospective study
    Junichi Kurebayashi
    Department of Breast and Thyroid Surgery, Kawasaki Medical School, Japan
    Breast Cancer 10:38-44. 2003
    ..To clarify this issue, the Tumor Marker Study Group of the Japanese Breast Cancer Society conducted a large-scaled retrospective study...
  32. ncbi request reprint Inhibition of HER1 signaling pathway enhances antitumor effect of endocrine therapy in breast cancer
    Junichi Kurebayashi
    Department of Breast and Thyroid Surgery, Kawasaki Medical School, 577 Matsushima, Kurashiki, Okayama 701 0192, Japan
    Breast Cancer 11:38-41. 2004
    ..The rationale and future perspectives of the combined use of STIs with endocrine therapy in breast cancer are discussed...
  33. doi request reprint The expression of monocyte chemotactic protein-1 in papillary thyroid carcinoma is correlated with lymph node metastasis and tumor recurrence
    Katsuhiro Tanaka
    Department of Breast and Thyroid Surgery, Kawasaki Medical School, Okayama, Japan, 2 Centocor Inc, Horsham, Pennsylvania, USA
    Thyroid 19:21-5. 2009
    ..The present study was performed to determine if there is a relationship between the expression of MCP-1 in papillary thyroid carcinoma (PTC) and factors indicative of aggressive behavior in this disease...
  34. ncbi request reprint Metastatic papillary thyroid carcinoma of the submandibular lymph nodes with extensive squamous metaplasia: report of a case
    Hironori Kunisue
    Department of Breast and Thyroid Surgery, Kawasaki Medical School, 577 Matsushima, Kurashiki, Okayama 701 0192, Japan
    Surg Today 33:751-4. 2003
    ....
  35. ncbi request reprint Expression of angiogenic factors including VEGFs and the effects of hypoxia and thalidomide on human myeloma cells
    Kenichiro Yata
    Department of Internal Medicine, Division of Hematology, Kawasaki Medical School, Okayama 701 0192, Japan
    Int J Oncol 22:165-73. 2003
    ..These findings may encourage the clinical use of anti-angiogenic agents for their cytostatic effects and the prevention of progression...
  36. doi request reprint [Bone-related events in breast cancer]
    Junichi Kurebayashi
    Kawasaki Medical School, Department of Breast and Thyroid Surgery
    Clin Calcium 18:447-54. 2008
    ..These effects cause unbalance of bone metabolism, loss of bone density and increase in the incidence of fractures. Improvement of these bone-related adverse effects and careful follow-ups are needed for breast cancer patients...
  37. ncbi request reprint [Molecular action mechanisms of hormone dependency in breast cancer]
    Junichi Kurebayashi
    Department of Breast and Thyroid Surgery, Kawasaki Medical School
    Nihon Rinsho 65:68-73. 2007
  38. ncbi request reprint [Additional effect of SERM: mammary gland]
    Junichi Kurebayashi
    Department of Breast and Thyroid Surgery, Kawasaki Medical School
    Clin Calcium 14:47-51. 2004
    ..In contrast, another SERM, raloxifene, has reported to have similar favorable adverse effects but no unfavorable effect on endometrium...
  39. doi request reprint Clinicopathological significance of Y416Src and Y527Src expression in breast cancer
    Naoki Kanomata
    Department of Pathology, Kawasaki Medical School, Kurashiki, Okayama, Japan
    J Clin Pathol 64:578-86. 2011
    ..To elucidate the clinicopathological significance of Y416Src and Y527Src expression in breast cancer, and to evaluate their usefulness as potential predictive markers for Src inhibitors...
  40. ncbi request reprint [Biomarkers in breast cancer]
    Junichi Kurebayashi
    Department of Breast and Thyroid Surgery, Kawasaki Medical School, 577 Matsushima, Kurashiki, Okayama 701 0192, Japan
    Gan To Kagaku Ryoho 31:1021-6. 2004
    ..Current status, clinical significance, problems and future directions on predictive factors for response to cytotoxic chemotherapy are also discussed...
  41. doi request reprint Antitumor and anticancer stem cell activity of a poly ADP-ribose polymerase inhibitor olaparib in breast cancer cells
    Toshiro Shimo
    Department of Breast and Thyroid Surgery, Kawasaki Medical School, 577 Matsushima, Kurashiki, Okayama, 701 0192, Japan
    Breast Cancer 21:75-85. 2014
    ..We investigated antitumor activity of olaparib in breast cancer cell lines derived from patients with nonfamilial sporadic breast cancer...
  42. ncbi request reprint Endocrine-resistant breast cancer: underlying mechanisms and strategies for overcoming resistance
    Junichi Kurebayashi
    Department of Breast and Thyroid Surgery, Kawasaki Medical School, 577 Matsushima, Kurashiki, Okayama 701 0192, Japan
    Breast Cancer 10:112-9. 2003
    ..Understanding the precise mechanisms that underlie endocrine resistance may enable clinicians to develop new strategies for retarding or overcoming endocrine resistance in breast cancer...
  43. pmc Analysis of clinical outcome of patients with poorly differentiated thyroid carcinoma
    Katsuhiro Tanaka
    Department of Breast and Thyroid Surgery, Kawasaki Medical School, 577 Matsushima, Kurashiki 701 0192, Japan
    ISRN Endocrinol 2011:308029. 2011
    ..547) significantly impacted cause-specific survival. Conclusion. Poor differentiation was an independent factor for survival. Distant relapse was significantly more common among PDTC patients, and systemic therapy might be warranted...
  44. ncbi request reprint Interleukin 10 abolishes the growth inhibitory effects of all-trans retinoic acid on human myeloma cells
    Takemi Otsuki
    Department of Hygiene, Division of Hematology, Kawasaki Medical School, Kurashiki, Japan
    Br J Haematol 116:787-95. 2002
    ..These characteristics may prove important for the clinical use of ATRA and should be considered before starting ATRA therapy for myeloma...
  45. ncbi request reprint [Postoperative adjuvant therapy for premenopausal patients with breast cancer]
    Junichi Kurebayashi
    Department of Breast and Thyroid Surgery, Kawasaki Medical School
    Nihon Rinsho 64:1963-9. 2006
    ..On-going clinical trials to resolve unanswered questions on the adjuvant therapy are also reviewed. Finally, future perspectives on the adjuvant therapy are discussed...
  46. ncbi request reprint [Tumor markers in breast cancer]
    Junichi Kurebayashi
    Dept of Breast and Thyroid Surgery, Kawasaki Medical School, Kurashiki, Okayama, Japan
    Gan To Kagaku Ryoho 31:2077-81. 2004
    ..Future directions of clinical and experimental research for breast cancer-orientated tumor markers are also discussed...
  47. ncbi request reprint [Biomarkers, tumor markers and prognostic markers in breast cancer]
    Junichi Kurebayashi
    Department of Breast and Thyroid Surgery, Kawasaki Medical School
    Nihon Rinsho 64:461-6. 2006
    ..Current status, clinical significance, problems and future directions on predictive markers for response to endocrine therapy and cytotoxic chemotherapy are also discussed...
  48. doi request reprint Long-term outcome of hypofractionated radiotherapy to the whole breast of Japanese women after breast-conserving surgery
    Takeaki Ishihara
    Department of Radiation Oncology, Kawasaki Medical School, 577, Matsushima, Kurashiki, Okayama, 701 0192, Japan
    Breast Cancer 21:40-6. 2014
    ..We report our institution's results from evaluation of the efficacy and safety of hypofractionated radiotherapy for Japanese women...
  49. ncbi request reprint [Retrospective analysis on efficacy and toxicity of paclitaxel-containing treatments in patients with advanced or recurrent breast cancer]
    Mai Hirono
    Dept of Breast and Thyroid Surgery, Kawasaki Medical School
    Gan To Kagaku Ryoho 31:723-7. 2004
    ..Paclitaxel seems to be a feasible, safe and active agent for patients with metastatic breast cancer...
  50. ncbi request reprint [Cancer prevention]
    Hideyuki Akaza
    Dept of Urology, Institute of Clinical Medicine, University of Tsukuba
    Gan To Kagaku Ryoho 32:1499-506. 2005
    ..Overall, cancer prevention is still in evolution. New approaches are needed, and new infrastructure will be needed at a government level to implement this...
  51. ncbi request reprint The selective tyrosine kinase inhibitor, STI571, inhibits growth of anaplastic thyroid cancer cells
    Alexei Podtcheko
    Department of Molecular Medicine, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki 852 8523, Japan
    J Clin Endocrinol Metab 88:1889-96. 2003
    ..Taken together, these results suggest that selective suppression of c-ABL activity by STI571 may represent a potential anticancer strategy for p53-mutated undifferentiated thyroid carcinomas...
  52. ncbi request reprint [Therapeutic effects of Anastrozole in patients with advanced and recurrent breast cancer]
    Sumiko Okubo
    Dept of Breast and Thyroid Surgery, Kawasaki Medical School
    Gan To Kagaku Ryoho 31:1527-31. 2004
    ....
  53. ncbi request reprint [Anti angiogenesis]
    Hideyuki Akaza
    Dept of Urology, University of Tsukuba
    Gan To Kagaku Ryoho 31:647-55. 2004
    ..Such surrogate markers of anti-angiogenic effect will be essential for optimising molecules and doses...
  54. ncbi request reprint [Retrospective study on utility of irinotecan hydrochloride in patients with advanced and recurrent breast cancer]
    Sumiko Okubo
    Dept of Breast and Thyroid Surgery, Kawasaki Medical School
    Gan To Kagaku Ryoho 30:1441-5. 2003
    ..The activity of first-line irinotecan therapy or the combined use of irinotecan with other agents should be investigated in clinical studies...
  55. ncbi request reprint Epigenetically controlled fibroblast growth factor receptor 2 signaling imposes on the RAS/BRAF/mitogen-activated protein kinase pathway to modulate thyroid cancer progression
    Tetsuo Kondo
    Department of Pathology, Princess Margaret Hospital, University Health Network, Toronto, Ontario, Canada
    Cancer Res 67:5461-70. 2007
    ..These data unmask an epigenetically controlled FGFR2 signal that imposes precisely on the intragenically modified BRAF/MAPK pathway to modulate thyroid cancer behavior...
  56. ncbi request reprint [Docetaxel administration for radioiodine-resistant patients with metastatic papillary thyroid carcinoma]
    Masahiko Ikeda
    Dept of Breast and Thyroid Surgery, Kawasaki Medical School
    Gan To Kagaku Ryoho 34:933-6. 2007
    ..Since no effective systemic treatment has been established for radioiodine-resistant patients with metastatic papillary thyroid carcinoma,docetaxel therapy was supposed to be a viable alternative for them...
  57. ncbi request reprint Capecitabine and paclitaxel combination chemotherapy for inoperable or recurrent breast cancer: a phase I dose-finding study by the Kinki Breast Cancer Study Group
    Norikazu Masuda
    Department of Surgery, Breast Oncology Group, Osaka National Hospital, 2 1 14, Honenzaka, Chuou ku, Osaka City, Osaka 540 0006, Japan
    Cancer Chemother Pharmacol 61:989-95. 2008
    ..We conducted a dose-finding study to identify the recommended 4-weekly XP regimen in patients with inoperable or recurrent breast cancer for phase II evaluation...
  58. doi request reprint Topoisomerase IIalpha-positive and BRCA1-negative phenotype: association with favorable response to epirubicin-based regimens for human breast cancers
    Yasuo Miyoshi
    Department of Breast and Endocrine Surgery, Osaka University Graduate School of Medicine, Osaka, Japan
    Cancer Lett 264:44-53. 2008
    ..05), or TOP2A-negative and BRCA1-negative (0%; P < 0.005). The TOP2A-positive and BRCA1-negative phenotype associates with a favorable response to epirubicin-based regimens...
  59. ncbi request reprint Enhanced B-Raf protein expression is independent of V600E mutant status in thyroid carcinomas
    Tetsuo Kondo
    Department of Pathology, University of Yamanashi, Chuo, Yamanashi 409 3898, Japan
    Hum Pathol 38:1810-8. 2007
    ....
  60. ncbi request reprint [Evaluation of safety and efficacy for bi-weekly Docetaxel and 5'-DFUR combination therapy in patients with advanced or recurrent breast cancer--Phase I study]
    Masahiko Ikeda
    Dept of Breast and Thyroid Surgery, Kawasaki Medical School
    Gan To Kagaku Ryoho 33:767-71. 2006
    ..Docetaxel is proved to express synergistic efficacy in combination with 5'-DFUR by induced dThdPase in vivo. But there are no clinical trials to evaluate efficacy of bi-weekly Docetaxel and 5'-DFUR combination therapy...
  61. ncbi request reprint Low nuclear grade but not cell proliferation predictive of pathological complete response to docetaxel in human breast cancers
    Yasuo Miyoshi
    Department of Breast and Endocrine Surgery, Osaka University Graduate School of Medicine, 2 2 Yamadaoka, Suita, Osaka 565 0871, Japan
    J Cancer Res Clin Oncol 134:561-7. 2008
    ..The aim of the present study was to investigate the relationship of various clinicopathological and biological parameters with pathological response to docetaxel in the neoadjuvant setting...
  62. ncbi request reprint [Efficacy of sequential treatment with anastrozole following exemestane compared with exemestane following anastrozole in patients with metastatic breast cancer]
    Masahiko Ikeda
    Dept of Breast and Thyroid Surgery, Kawasaki Medical School
    Gan To Kagaku Ryoho 35:261-5. 2008
    ..Though it is supposed that they can be administered sequentially because of their little cross-resistant effect, it is not definite which sequential treatment is best...
  63. ncbi request reprint [Therapeutic efficacy of capecitabine on advanced and recurrent breast cancer with special reference to time to progression]
    Shigeo Shiiki
    Dept of Breast and Thyroid Surgery, Kawasaki Medical School
    Gan To Kagaku Ryoho 33:1431-5. 2006
    ..absence) and PS (< or =2 vs. 3< or =) were independent factors affecting TTP. Capecitabine is expected to prolong the length of survival in patients who are able to continue treatment for 6 months or longer...